Interaction of vectors and parental viruses with the host genome

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 35-40

  Gil Farina, Irene ^a   Schmidt, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; CARCINOGENICITY; CHROMATIN; GENE EXPRESSION; GENOME; GENOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; NONHUMAN; PARVOVIRIDAE; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS REPLICATION; ANIMAL; CARCINOGENESIS; DEPENDOPARVOVIRUS; DNA DAMAGE; GENE VECTOR; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; PHYSIOLOGY; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; CARCINOGENESIS; DEPENDOVIRUS; DNA DAMAGE; GENETIC VECTORS; HIV; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS INTEGRATION;

EID: 84979518308     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.07.004     Document Type: Review

References (59)

1. 1 Di Santo, R., Inhibiting the HIV integration process: past, present, and the future. J Med Chem 57 (2014), 539–566.
2. 2 Maldarelli, F., The role of HIV integration in viral persistence: no more whistling past the proviral graveyard. J Clin Invest 126 (2016), 438–447.
3. 3 Craigie, R., Bushman, F.D., Host factors in retroviral integration and the selection of integration target sites. Microbiol Spectr, 2014, 2.
4. 4• Cremer, T., Cremer, M., Hübner, B., Strickfaden, H., Smeets, D., Popken, J., Sterr, M., Markaki, Y., Rippe, K., Cremer, C., The 4D nucleome: evidence for a dynamic nuclear landscape based on co-aligned active and inactive nuclear compartments. FEBS Lett 589 (2015), 2931–2943 The authors provide a full review of concepts and techniques regarding the study of nuclear architecture.
5. 5•• Wong, R.W., Mamede, J.I., Hope, T.J., Impact of nucleoporin-mediated chromatin localization and nuclear architecture on HIV integration site selection. J Virol 89 (2015), 9702–9705 This article reviews the HIV trafficking through the nuclear pore complex and the cellular components involved.
6. 6 Marini, B., Kertesz-Farkas, A., Ali, H., Lucic, B., Lisek, K., Manganaro, L., Pongor, S., Luzzati, R., Recchia, A., Mavilio, F., et al. Nuclear architecture dictates HIV-1 integration site selection. Nature 521 (2015), 227–231.
7. 7 Lelek, M., Casartelli, N., Pellin, D., Rizzi, E., Souque, P., Severgnini, M., Di Serio, C., Fricke, T., Diaz-Griffero, F., Zimmer, C., et al. Chromatin organization at the nuclear pore favours HIV replication. Nat Commun, 6, 2015, 6483.
8. 8 Ocwieja, K.E., Brady, T.L., Ronen, K., Huegel, A., Roth, S.L., Schaller, T., James, L.C., Towers, G.J., Young, J.A.T., Chanda, S.K., et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog, 7, 2011, e1001313.
9. 9 Schaller, T., Ocwieja, K.E., Rasaiyaah, J., Price, A.J., Brady, T.L., Roth, S.L., Hué, S., Fletcher, A.J., Lee, K., KewalRamani, V.N., et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog, 7, 2011, e1002439.
10. 10 Campbell, E.M., Hope, T.J., HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol 13 (2015), 471–483.
11. 11 Debyser, Z., Christ, F., De Rijck, J., Gijsbers, R., Host factors for retroviral integration site selection. Trends Biochem Sci 40 (2015), 108–116.
12. 12 Gijsbers, R., Ronen, K., Vets, S., Malani, N., De Rijck, J., McNeely, M., Bushman, F.D., Debyser, Z., LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 18 (2010), 552–560.
13. 13 Singh, P.K., Plumb, M.R., Ferris, A.L., Iben, J.R., Wu, X., Fadel, H.J., Luke, B.T., Esnault, C., Poeschla, E.M., Hughes, S.H., et al. LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. Genes Dev 29 (2015), 2287–2297.
14. 14 Kvaratskhelia, M., Sharma, A., Larue, R.C., Serrao, E., Engelman, A., Molecular mechanisms of retroviral integration site selection. Nucleic Acids Res 42 (2014), 10209–10225.
15. 15 Boehm, D., Conrad, R.J., Ott, M., Bromodomain proteins in HIV infection. Viruses 5 (2013), 1571–1586.
16. 16 Maldarelli, F., Wu, X., Su, L., Simonetti, F.R., Shao, W., Hill, S., Spindler, J., Ferris, A.L., Mellors, J.W., Kearney, M.F., et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345 (2014), 179–183.
17. 17 Wagner, T.A., McLaughlin, S., Garg, K., Cheung, C.Y.K., Larsen, B.B., Styrchak, S., Huang, H.C., Edlefsen, P.T., Mullins, J.I., Frenkel, L.M., HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345 (2014), 570–573.
18. 18 Zhou, S., Fatima, S., Ma, Z., Wang, Y.-D., Lu, T., Janke, L.J., Du, Y., Sorrentino, B.P., Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes. Mol Ther, 2016, 10.1038/mt.2016.55.
19. 19 Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009), 818–823.
20. 20 Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158.
21. 21 Papanikolaou, E., Paruzynski, A., Kasampalidis, I., Deichmann, A., Stamateris, E., Schmidt, M., von Kalle, C., Anagnou, N.P., Cell cycle status of CD34(+) hemopoietic stem cells determines lentiviral integration in actively transcribed and development-related genes. Mol Ther 23 (2015), 683–696.
22. 22 McAllister, R.G., Liu, J., Woods, M.W., Tom, S.K., Rupar, C.A., Barr, S.D., Lentivector integration sites in ependymal cells from a model of metachromatic leukodystrophy: non-B DNA as a new factor influencing integration. Mol Ther Nucleic Acids, 3, 2014, e187.
23. 23 Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
24. 24 Palfi, S., Gurruchaga, J.M., Ralph, G.S., Lepetit, H., Lavisse, S., Buttery, P.C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383 (2014), 1138–1146.
25. 25 Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M.C., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. Science, 341, 2013, 1233151.
26. 26 Hacein-Bey Abina, S., Gaspar, H.B., Blondeau, J., Caccavelli, L., Charrier, S., Buckland, K., Picard, C., Six, E., Himoudi, N., Gilmour, K., et al. Outcomes following gene therapy in patients with severe Wiskott–Aldrich syndrome. JAMA 313 (2015), 1550–1563.
27. 27 Moiani, A., Paleari, Y., Sartori, D., Mezzadra, R., Miccio, A., Cattoglio, C., Cocchiarella, F., Lidonnici, M.R., Ferrari, G., Mavilio, F., Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122 (2012), 1653–1666.
28. 28 Cesana, D., Sgualdino, J., Rudilosso, L., Merella, S., Naldini, L., Montini, E., Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122 (2012), 1667–1676.
29. 29• Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 22 (2014), 774–785 The authors analyzed the oncogenic potential and the integration profile associated of several lentiviral vector designs in a murine model of genotoxicity.
30. 30 Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N.E., Popa-Wagner, R., Kleinschmidt, J.a., Properties of the adeno-associated virus assembly-activating protein. J Virol 86 (2012), 13038–13048.
31. 31 Bardelli, M., Zárate-Pérez, F., Agúndez, L., Linden, R.M., Escalante, C.R., Henckaerts, E., Identification of a functionally relevant AAV Rep68 oligomeric interface. J Virol, 2016, 10.1128/JVI.00356-16.
32. 32 Earley, L.F., Kawano, Y., Adachi, K., Sun, X.-X., Dai, M.-S., Nakai, H., Identification and characterization of nuclear and nucleolar localization signals in the adeno-associated virus serotype 2 assembly-activating protein. J Virol 89 (2015), 3038–3048.
33. 33 Musayev, F.N., Zarate-Perez, F., Bishop, C., Burgner, J.W., Escalante, C.R., Structural insights into the assembly of the adeno-associated virus type 2 Rep68 protein on the integration site AAVS1. J Biol Chem 290 (2015), 27487–27499.
34. 34 Dutheil, N., Smith, S.C., Agúndez, L., Vincent-Mistiaen, Z.I., Escalante, C.R., Linden, R.M., Henckaerts, E., Adeno-associated virus Rep represses the human integration site promoter by two pathways that are similar to those required for the regulation of the viral p5 promoter. J Virol 88 (2014), 8227–8241.
35. 35 Janovitz, T., Klein, I.a., Oliveira, T., Mukherjee, P., Nussenzweig, M.C., Sadelain, M., Falck-Pedersen, E., High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol 87 (2013), 8559–8568.
36. 36 Hüser, D., Gogol-Döring, A., Chen, W., Heilbronn, R., AAV Type 2 wild-type and vector-mediated genomic integration profiles in human diploid fibroblasts analyzed by 3rd generation PacBio DNA sequencing. J Virol 88 (2014), 11253–11263.
37. 37 Janovitz, T., Sadelain, M., Falck-Pedersen, E., Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints. Virol J, 11, 2014, 15.
38. 38•• Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47 (2015), 1187–1193 The authors analyzed wild-type AAv integration by targeted and whole-exome sequencing in human hepatocellular carcinoma biopsies and found clonally expanded integrations in genes previously associated with liver cancer development.
39. 39 Fujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H., Taniguchi, H., Kawakami, Y., Ueno, M., et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet, 2016, 10.1038/ng.3547.
40. 40 Petri, K., Gabriel, R., Agundez, L., Fronza, R., Afzal, S., Kaeppel, C., Linden, R.M., Henckaerts, E., Schmidt, M., Presence of a trs-like motif promotes Rep-mediated wild-type adeno-associated virus type 2 integration. J Virol 89 (2015), 7428–7432.
41. 41 Janovitz, T., Oliveira, T., Sadelain, M., Falck-Pedersen, E., Imperiale, M.J., Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing. J Virol 88 (2014), 2481–2488.
42. 42 Chen, C.-L., Jensen, R.L., Schnepp, B.C., Connell, M.J., Shell, R., Sferra, T.J., Bartlett, J.S., Clark, K.R., Johnson, P.R., Molecular characterization of adeno-associated viruses infecting children. J Virol 79 (2005), 14781–14792.
43. 43 Gao, G., Vandenberghe, L.H., Alvira, M.R., Lu, Y., Calcedo, R., Zhou, X., Wilson, J.M., Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78 (2004), 6381–6388.
44. 44 Berns, K.I., Byrne, B.J., Flotte, T.R., Gao, G., Hauswirth, W.W., Herzog, R.W., Muzyczka, N., VandenDriessche, T., Xiao, X., Zolotukhin, S., et al. Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther 26 (2015), 779–781.
45. 45 Büning, H., Schmidt, M., Adeno-associated vector toxicity-to be or not to be?. Mol Ther 23 (2015), 1673–1675.
46. 46 Schmidt, M., Gil-Farina, I., Büning, H., Reply to “Wild-type AAV insertions in hepatocellular carcinoma do not inform debate over genotoxicity risk of vectorized AAV”. Mol Ther 24 (2016), 661–662.
47. 47 Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20 (2013), 361–369.
48. 48 Nowrouzi, A., Penaud-Budloo, M., Kaeppel, C., Appelt, U., Le Guiner, C., Moullier, P., von Kalle, C., Snyder, R.O., Schmidt, M., Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 20 (2012), 1177–1186.
49. 49 Hüser, D., Gogol-Döring, A., Chen, W., Heilbronn, R., Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing. J Virol 88 (2014), 11253–11263.
50. 50 McCarty, D.M., Young, S.M., Samulski, R.J., Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38 (2004), 819–845.
51. 51 Nakai, H., Wu, X., Fuess, S., Storm, T.a., Munroe, D., Montini, E., Burgess, S.M., Grompe, M., Kay, M.a., Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79 (2005), 3606–3614.
52. 52 Inagaki, K., Lewis, S.M., Wu, X., Ma, C., Munroe, D.J., Fuess, S., Storm, T.a., Kay, M.A., Nakai, H., DNA palindromes with a modest arm length of greater, similar 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. J Virol 81 (2007), 11290–11303.
53. 53• Kaeppel, C., Beattie, S.G., Fronza, R., Van Logtenstein, R., Salmon, F., Schmidt, S., Wolf, S., Nowrouzi, A., Glimm, H., Kalle, C.Von, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 19 (2013), 889–891 The authors analyzed AAV vector integration in murine and human muscle biopsies and provided the first evidence of AAv integration within the mitochondrial genome.
54. 54 Miller, D.G., Petek, L.M., Russell, D.W., Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 36 (2004), 767–773.
55. 55 Pañeda, A., Lopez-Franco, E., Kaeppel, C., Unzu, C., Gil-Royo, A.G., D'Avola, D., Beattie, S.G., Olagüe, C., Ferrero, R., Sampedro, A., et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther 24 (2013), 1007–1017.
56. 56 Gil-Farina, I., Fronza, R., Kaeppel, C., Lopez-Franco, E., Ferreira, V., D'Avola, D., Benito, A., Prieto, J., Petry, H., Gonzalez-Aseguinolaza, G., et al. Recombinant AAV integration is not associated with hepatic genotoxicity in non-human primates and patients. Mol Ther, 2016, 10.1038/mt.2016.52.
57. 57 Li, H., Malani, N., Hamilton, S.R., Schlachterman, A., Bussadori, G., Edmonson, S.E., Shah, R., Arruda, V.R., Mingozzi, F., Wright, J.F., et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 117 (2011), 3311–3319.
58. 58 Chandler, R.J., LaFave, M.C., Varshney, G.K., Trivedi, N.S., Carrillo-Carrasco, N., Senac, J.S., Wu, W., Hoffmann, V., Elkahloun, A.G., Burgess, S.M., et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 125 (2015), 870–880.
59. 59 Donsante, A., Miller, D.G., Li, Y., Vogler, C., Brunt, E.M., Russell, D.W., Sands, M.S., AAV vector integration sites in mouse hepatocellular carcinoma. Science, 317, 2007, 477.